Vivos Therapeutics (VVOS) Total Liabilities (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Total Liabilities for 8 consecutive years, with $28.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 30.84% year-over-year to $28.1 million in Q2 2026; TTM through Jun 2026 was $28.1 million, a 30.84% increase from a year earlier, with the FY2025 full-year figure at $26.7 million, up 264.28% from the prior year.
• Total Liabilities was $28.1 million for Q2 2026 at Vivos Therapeutics, up from $26.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $28.1 million in Q2 2026 and troughed at $6.9 million in Q1 2025.
• A 5-year average of $13.7 million and a median of $10.2 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities plunged 38.51% in 2025 and jumped 281.3% in 2026, its largest moves.
• Over 5 years, Total Liabilities stood at $8.9 million in 2022, then increased by 15.7% to $10.3 million in 2023, then slipped by 28.97% to $7.3 million in 2024, then jumped by 264.28% to $26.7 million in 2025, then gained by 5.35% to $28.1 million in 2026.
• The last three Total Liabilities figures came in at $28.1 million (Q2 2026), $26.3 million (Q1 2026), and $26.7 million (Q4 2025), per Business Quant data.